Exploratory Clinical Trial for Efficacy and Safety of Short-term (3 days) Enoxaparin on Prevention of Venous Thromboembolism after Gastric Cancer Surgery

Exploratory Clinical Trial for Efficacy and Safety of Short-term (3 days) Enoxaparin on Prevention of Venous Thromboembolism after Gastric Cancer Surgery - Efficacy and Safety of Short-term (3 days) Enoxaparin on Gastric Cancer Surgery

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000020235

Enrollment

Registered

2016-01-01

Start date

2016-03-16

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric cancer

Interventions

Subcutaneous injection of enoxaparin (2000IU, twice a day, from night of the 1st day to morning of the 4th day, 6 times in total) in combination with intermittent pneumatic compression

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients with histologically-diagnosed gastric cancer who are planned to receive total, distal, proximal or partial gastrectomy (surgical approach do not matter) 2) Patients over 40 years of age 3) Patients who can give written informed concent

Exclusion criteria

Exclusion criteria: 1) Patients with past history of venous thromboembolism 2) Patients with past history of allergic reaction to heparin or heparinoid (including low molecular weight heparin) 3) Patients with active bleeding (except for bleeding from gastric cancer planned to be resected by surgery) 4) Patients with acute bacterial endocarditis 5) Patients with severe renal dysfunction (Ccr < 30mL/min) 6) Patients with past history of heparin-induced thrombocytopenia 7) Patients who are otherwise judged by the investigator as unsuitable for enrollment

Design outcomes

Primary

Measure	Time frame
Incidence of venous thromboembolism at 8 to 14 days after surgery	—

Secondary

Measure	Time frame
Incidence of bleeding-related adverse events	—

Countries

Japan

Contacts

Public ContactShinji Kuroda

Okayama University Gastroenterological Surgery

shinkuro@okayama-u.ac.jp086-235-7257

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026